Biofortuna raises fresh funding for growth

MOLECULAR diagnostics company Biofortuna has secured a £1.3m investment to expand its business here and in the US.

The company based at Brombrough, Wirral, raised the funds with the support of all current investors – Enterprise Ventures, the Foresight Group (UK), Catapult Venture Managers, Merseyside Special Investment Fund, private investors and management.  

The new funds will enable the business to expand its freeze drying and manufacturing capability to support both its custom service clients and the US launch of its SSPGo HLA range of products.
 
Biofortuna has developed a unique method to stabilise molecular diagnostic products using its proprietary freeze-dried technology.

Dr Simon Douglas, chief executive of Biofortuna said: “This investment will enable Biofortuna to grow its freeze dried development and manufacturing capacity.  With an increasing number of companies coming to us to stabilise their products we need to expand our freeze drying capability to complement our already established  diagnostic development expertise.”
 
Julian Viggars of Enterprise Ventures, which first invested in Biofortuna on its launch in 2008, said: “Biofortuna’s technology helps increase laboratory productivity and improve quality in clinical testing and patient care.

“This latest investment will help it meet growing demand and strengthen its presence in the US market.”